Slide 1: Immuron CEO presentation to Coffee Microcaps Conference
Immuron CEO, Steven Lydeamore presentation to Coffee Microcaps Conference Melbourne, Australia, July 25, 2025: Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting virtually at the Coffee Microcaps Conference on Friday 25th Ju
Slide 2: Immuron Platform Technology
Immuron Platform Technology Immuron’s proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper-immune bovine colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally active. Bovine
Slide 3: References and forward-looking statements
them. 91% of the users experienced an improvement in daily life and 98% would recommend PROIBS® to someone else. To learn more please check: www.proibs.eu. Irritable bowel syndrome (IBS) is a common condition where you experience symptoms related to your digestive system. This is sometimes linked to
Slide 4: Coffee Microcaps
NASDAQ: IMRN ASX: IMC For personal use only Coffee Microcaps Steven Lydeamore Chief Executive Officer 25 July 2025
Slide 5: Safe Harbor Statement
SAFE HARBOR STATEMENT C e r ta i n state m e n t s m a d e i n t h i s p re s e nta t i o n a re fo r wa rd - l o o k i n g state m e n t s a n d a re b a s e d o n I m m u ro n ’s c u r re nt ex p e c tat i o n s , e st i m ate s a n d p ro j e c t i o n s . Wo rd s s u c h a s For personal use onl
Slide 6: Executive summary
Executive summary Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only Company Overview Financial Snapshot Two commercially available
Slide 7: Revenue generating with strong pipeline
REVENUE GENERATING WITH STRONG PIPELINE Immuron Ltd (NASDAQ:IMRN) (ASX:IMC) is a globally integrated biopharmaceutical company focused on developing, and commercialising, oral immunotherapeutics for the treatment of gut mediated diseases For personal use only 7 March 2025 25 July 2025 December 2024
Slide 8: Opportunity to Convert Billion Dollar Traveller's Diarrhoea Market
Opportunity to Convert Billion Dollar Traveller’s Diarrhoea Market from Relief to Prevention by Travelan® Billion Dollar Market Traveller’s diarrhoea treatment market is large and growing at a CAGR of ~7%1 For personal use only Industry tailwinds International travel continues to grow Travel to high
Slide 9: Travelan continued strong sales growth
Travelan® continued strong sales growth Global For personal use only + FY2026 AUD$7.3 million up 49% on prior year Global Year to Date Net Sales ($AUD) $8,000,000 $7,000,000 $6,000,000 Australia $5,000,000 + FY2026 AUD$5.2 million up 40% on prior year $4,000,000 $3,000,000 + Secured core ranging in
Slide 10: Expansion of Travelan Distribution
EXPANSION OF TRAVELAN® DISTRIBUTION For personal use only
Slide 11: Consumer marketing activity driving Travelan sales growth
CONSUMER MARKETING ACTIVITY DRIVING TRAVELAN® SALES GROWTH We continue to drive awareness, For personal use only consideration and engagement o Ranging across major retailers (Australia, Canada) o In-store positioning and promotion o Retailer catalogues o Search and social media marketing o Social c
Slide 12: Status of product portfolio and key milestones
STATUS OF PRODUCT PORTFOLIO AND KEY MILESTONES For personal use only Peak U.S. Current Indication Compound Preclinical Phase 1 Phase 2 Phase 3 Registration Collaborator 2H 2025 1H 2026 sales Status Uniformed 100% of 866 Traveller's Diarrhoea Travelan® US$ 102 m Services participants Topline Data Uni
Slide 13: Immuron's clinical programs – opportunity assessment
IMMURON’S CLINICAL PROGRAMS – OPPORTUNITY ASSESSMENT › Immuron’s development of IMM-124E (hyperimmune › Infectious disease experts reacted favorably to the IMM-529 For personal use only bovine colostrum) as a prescription medication has MOA, and its unique ability to target three elements of the the
Slide 14: World first triple mechanism of action for CDI
WORLD FIRST TRIPLE MECHANISM OF ACTION FOR CDI IMM-529: pre-IND filed with FDA July 2024; successful pre-IND meeting Indication / Target IMM-529 will be indicated for the treatment of recurrent C. difficile For personal use only Population infection Product • Novel antibody-containing therapeutic wh
Slide 15: Positive results support Travelan progress to phase 3
Positive results support Travelan® progress to phase 3 For personal use only IMM-124E Phase 2 + Healthy volunteers were recruited and randomized to receive a single daily oral Travelan® topline clinical dose of 1200 mg of Travelan® or placebo. Dosing commenced 2 days prior to trial results demonstra
Slide 16: IMM-124E Phase 3 strategy
IMM-124E Phase 3 strategy Pre 2024 2025 2026 Post For personal use only Phase 1 clinical study Phase 2 clinical study Clinical Study Report End of Phase 2 FDA meeting Initiate Phase 3 (Baltimore, 1996) (Baltimore) January 2025 Trial duration ~ 2 years Phase 2 clinical study Additional topline data (
Slide 17: Upcoming Milestones
Upcoming Milestones Revenue For personal use only + Continued quarter on quarter growth of Travelan® from growth drivers + Australian launch of ProIBS Clinical IMM-124E (Travelan®): Traveller’s Diarrhoea + IMM-124E: completed 100% recruitment, randomization and deployment (Phase 4; n=866) + IMM-124E
Slide 18: Scientific references
Scientific references Travelan® (IMM-124E) For personal use only Travelan® has been shown to reduce both the incidence and severity of ETEC- Scandinavian Journal of Gastroenterology, 46:7-8, 862-868, DOI: 10.3109/00365521.2011.574726 induced diarrhea in up to 90% of volunteers Clinical Evaluation of
Slide 19: Steven Lydeamore contact information
For personal use only STEVEN LYDEAMORE CHIEF EXECUTIVE OFFICER IMMURON LIMITED CONTACT INFORMATION: EMAIL: STEVE@IMMURON.COM PHONE: AUSTRALIA: +61 438 027 172